title: [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide].
abstract: Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks. Significant decrease of systolic and diastolic arterial pressure was established during period B as compared with period. A. The addition of isoptin to the treatment during period C led to additional reduction of arterial pressure, with no manifestations of severe adverse effects, as observed in 15,6 per cent of the treated patients. The treatment of essential hypertension with isoptin and esidrex is effective and well tolerated with no reciprocal potentiation of the adverse effects of the two preparations, broadening the possibility of successful treatment of essential hypertension.
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D014700:Verapamil / Q000627:therapeutic use*
chemical_list: D006852:Hydrochlorothiazide; D014700:Verapamil
vernacular_title: Lechenie na esentsialnata khipertoniia (khipertonichnata bolest) s verapamil i khidrokhlortiazid.